Technology to restore vision through the use of a component of green algae developed by Dr. Zhou-Han Pan, professor and scientific director of the Ligon Research Center of Vision at the Kresge Eye Institute at Wayne State University, and licensed to RetroSense Therapeutics, a biotechnology company dedicated to developing gene therapy approaches to vision restoration, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. patent application (No. 12/299,574).
[More]
The energetic and radiant hue of emerald green has been declared the spring color of 2013. While green shirts, pants and jackets will be seen everywhere this season, so should green food on your plate.
[More]
An international group of investigators has identified seven new genetic regions associated with age-related macular degeneration (AMD), a common cause of blindness in older individuals. The findings, reported online March 3 in Nature Genetics, could point to new biological pathways and therapeutic targets for AMD.
[More]
Oraya Therapeutics, Inc. today announced that one of the patients who successfully was treated for wet age-related macular degeneration (AMD) with Oraya Therapy during the INTREPID clinical trial has released data showing he has experienced significant, sustained vision improvement more than two years after treatment in his right eye, without any subsequent anti-vascular endothelial growth factor (anti-VEGF) injections or other treatment.
[More]
Levels of high-sensitivity C-reactive protein predict the risk for age-related macular degeneration and diabetic macular edema, show results of two independent studies published in JAMA Ophthalmology.
[More]
Napoleone Ferrara, MD, PhD, the molecular biologist credited with helping decipher how tumors grow and now senior deputy director for basic sciences at the University of California, San Diego Moores Cancer Center, was today named one of 11 recipients of the inaugural Breakthrough Prize in Life Sciences, which comes with a $3 million cash award.
[More]
Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation announced today that Immune is initiating, following authorization from Israeli health authorities, a Phase II double-blind placebo controlled study with its lead drug, bertilimumab, in patients with moderate-to-severe ulcerative colitis.
[More]
The major risk alleles that influence the development of age-related macular degeneration do not predict response to therapy for the condition, a substudy of the CATT trial indicates.
[More]
Regeneron Pharmaceuticals, Inc. today announced financial and operating results for the fourth quarter and full year 2012 and provided an update on development programs.
[More]
New findings from a landmark clinical trial show that although certain gene variants may predict whether a person is likely to develop age-related macular degeneration (AMD), a potentially blinding eye disease that afflicts more than nine million Americans, these genes do not predict how patients will respond to Lucentis- and Avastin-, the two medications most widely used to treat the "wet" form of AMD.
[More]
An international team of scientists led by King's College London has discovered 24 new genes that cause refractive errors and myopia (short-sightedness).
[More]
BrightFocus Foundation, a nonprofit organization that funds research worldwide to save sight and mind, today released the results of a survey of more than 170 leading biomedical scientists that explores the most significant barriers to progress in ending brain and eye diseases.
[More]
A 20-page large-print booklet and a series of videos to help people adapt to life with low vision are available from the National Eye Institute (NEI), a part of the National Institutes of Health. The materials were released during Low Vision Awareness Month, February 2013.
[More]
Doctors may one day treat some forms of blindness by altering the genetic program of the light-sensing cells of the eye, according to scientists at Washington University School of Medicine in St. Louis.
[More]
Instead of granting automatic pay increases, N.Y. City's public hospital system will pay them based on how well they reduce costs, increase patient satisfaction and improve the quality of care. The Health and Hospitals Corporation, which runs the city's 11 public hospitals, deserves praise for an ambitious proposal that will need to be refined as it is put into practice.
[More]
This week, a study published in the journal JAMA Internal Medicine, explored the connection between regular aspirin use and the potential risks for developing the blinding eye disease, macular degeneration. As a result, there is increased confusion and anxiety in the general public about whether aspirin can harm your vision and what to do if you need the heart-protective therapy.
[More]
People who take aspirin more than once per week may be at increased risk for developing neovascular age-related macular degeneration, a prospective study has found.
[More]
Regular aspirin use appears to be associated with an increased risk of neovascular age-related macular degeneration (AMD), which is a leading cause of blindness in older people, and it appears to be independent of a history of cardiovascular disease and smoking, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication.
[More]
AMD is the leading cause of vision loss in anyone over 50 and globally in 2010 it was estimated to cost $340 billion to treat AMD. The costs are set to spiral over the next 20 years and really over burden the healthcare system unless people start to take preventative action.
[More]
Abnormalities of eye movement and fixation may contribute to difficulty in perceiving and recognizing faces among older adults with age-related macular degeneration (AMD), suggests a study "Abnormal Fixation in Individuals with AMD when Viewing an Image of a Face" appearing in the January issue of Optometry and Vision Science, official journal of the American Academy of Optometry.
[More]